JP2019515646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515646A5 JP2019515646A5 JP2018544554A JP2018544554A JP2019515646A5 JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5 JP 2018544554 A JP2018544554 A JP 2018544554A JP 2018544554 A JP2018544554 A JP 2018544554A JP 2019515646 A5 JP2019515646 A5 JP 2019515646A5
- Authority
- JP
- Japan
- Prior art keywords
- binding member
- seq
- member according
- sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 claims 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057 | 2016-02-25 | ||
| EP16020057.2 | 2016-02-25 | ||
| PCT/EP2017/054367 WO2017144681A1 (en) | 2016-02-25 | 2017-02-24 | Binding members to pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515646A JP2019515646A (ja) | 2019-06-13 |
| JP2019515646A5 true JP2019515646A5 (OSRAM) | 2020-04-09 |
| JP7080819B2 JP7080819B2 (ja) | 2022-06-06 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545230A Active JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2018544554A Active JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545230A Active JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20190048085A1 (OSRAM) |
| EP (3) | EP3420001B1 (OSRAM) |
| JP (3) | JP7082574B2 (OSRAM) |
| KR (2) | KR20190003938A (OSRAM) |
| CN (3) | CN116082505A (OSRAM) |
| AU (2) | AU2017224843A1 (OSRAM) |
| BR (2) | BR112018067698A2 (OSRAM) |
| CA (2) | CA3014067A1 (OSRAM) |
| ES (1) | ES2903408T3 (OSRAM) |
| RU (2) | RU2018128464A (OSRAM) |
| SG (2) | SG11201807188VA (OSRAM) |
| WO (2) | WO2017144681A1 (OSRAM) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
| BR112018067698A2 (pt) * | 2016-02-25 | 2019-01-08 | Cell Medica Switzerland Ag | células modificadas para imunoterapia |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| GB201617714D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| MD3551221T2 (ro) | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| KR102523318B1 (ko) | 2016-12-16 | 2023-04-18 | 비-모젠 바이오테크놀로지스, 인크. | 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법 |
| MX2019009772A (es) | 2017-02-21 | 2019-12-02 | Regeneron Pharma | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| MX2019012849A (es) | 2017-04-28 | 2019-11-28 | Five Prime Therapeutics Inc | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. |
| EP3728305A1 (en) | 2017-12-20 | 2020-10-28 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
| KR102795692B1 (ko) * | 2018-01-19 | 2025-04-16 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 키메라 항원 수용체를 발현하는 조절 t 세포 |
| EP3759146A1 (en) | 2018-03-02 | 2021-01-06 | CDR-Life AG | Trispecific antigen binding proteins |
| EP3774920A4 (en) * | 2018-03-29 | 2022-01-05 | Adagene Inc. | ANTI-PD-L1 ANTIBODIES AND USE OF THESE LATEST |
| KR20210015842A (ko) * | 2018-06-04 | 2021-02-10 | 디아테바 에스.알.엘. | 항-cd99 다이아바디 또는 igg 항체 및 그의 용도 |
| CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| CN112119094B (zh) * | 2018-06-29 | 2024-11-22 | Y生物股份有限公司 | 与淋巴细胞活化基因3特异性结合的单克隆抗体及其用途 |
| KR20210042909A (ko) | 2018-07-09 | 2021-04-20 | 프레시전 인코포레이티드 | 융합 구조물 및 그의 이용 방법 |
| SG11202103234RA (en) * | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US10993967B2 (en) | 2018-10-17 | 2021-05-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US20210369776A1 (en) * | 2018-12-06 | 2021-12-02 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| WO2020135559A1 (en) * | 2018-12-26 | 2020-07-02 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| MX2021009020A (es) * | 2019-01-28 | 2021-09-28 | Xyphos Biosciences Inc | Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car. |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| EP3953372A4 (en) * | 2019-03-26 | 2022-11-02 | The Regents of The University of California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN118344479A (zh) * | 2019-06-12 | 2024-07-16 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| EP3994176A4 (en) * | 2019-07-02 | 2023-09-20 | Telix International Pty Ltd | Antibodies against caix with reduced affinity for the neonatal fc receptor |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| PH12022551078A1 (en) * | 2019-11-04 | 2024-06-19 | Regeneron Pharma | Combination therapy to treat brain cancer |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| WO2021113307A2 (en) * | 2019-12-02 | 2021-06-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| CN115103857B (zh) * | 2019-12-28 | 2025-12-19 | 上海细胞治疗集团股份有限公司 | 表达免疫调节分子的细胞和表达免疫调节分子的系统 |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| JP2023519926A (ja) * | 2020-03-23 | 2023-05-15 | キュリジン カンパニー，リミテッド | 二重特異性核酸分子を含む抗癌ウイルスの構造 |
| JP2023526605A (ja) * | 2020-05-14 | 2023-06-22 | ヴィルトゥオーソ ビンコ，インク． | ヒト化ｃｄ３８およびｉｃａｍ１抗体、ならびにそれらの使用 |
| US20230293691A1 (en) * | 2020-06-11 | 2023-09-21 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
| CN115916828A (zh) * | 2020-06-25 | 2023-04-04 | 普洛迈博生物技术公司 | Pd-l1-特异性抗体和抗pd-l1-car-t细胞 |
| AU2021305234A1 (en) | 2020-07-10 | 2023-02-09 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| IL302568A (en) * | 2020-11-04 | 2023-07-01 | Senti Biosciences Inc | Protein payload release |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| IL303149A (en) * | 2020-11-30 | 2023-07-01 | Fred Hutchinson Cancer Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| US20250179196A1 (en) * | 2021-07-30 | 2025-06-05 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
| EP4384642A4 (en) | 2021-08-13 | 2025-10-22 | Inovio Pharmaceuticals Inc | COMBINATION THERAPY TO TREAT BRAIN CANCER |
| CN118176017A (zh) * | 2021-10-26 | 2024-06-11 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| JP2025504557A (ja) * | 2022-01-28 | 2025-02-12 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ナチュラルキラーｔ細胞及びそれを使用する方法 |
| CN118005806A (zh) * | 2024-02-08 | 2024-05-10 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Ｐｄ−１に対し特異性を有する物質 |
| JP2006508638A (ja) | 2002-05-22 | 2006-03-16 | エスバテック・アーゲー | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
| NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| WO2009000099A2 (en) | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| BRPI0914663A2 (pt) | 2008-06-25 | 2015-10-20 | Esbatech Alcon Biomed Res Unit | humanização de anticorpos de coelho usando uma estrutura de anticorpo universal |
| PT3241843T (pt) | 2008-06-25 | 2021-09-10 | Novartis Ag | Otimização da solubilidade de imunoligantes |
| US8217149B2 (en) * | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| US9175082B2 (en) * | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| CA2875918A1 (en) * | 2012-06-06 | 2013-12-12 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| MX378463B (es) * | 2013-02-26 | 2025-03-10 | Memorial Sloan Kettering Cancer Center | Composiciones y usos de las mismas para inmunoterapia. |
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | Novel antibody frameworks |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| ES2939760T3 (es) * | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| EP4166148A1 (en) * | 2014-06-06 | 2023-04-19 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| BR112017000497B1 (pt) * | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| JP6810685B2 (ja) | 2014-09-04 | 2021-01-06 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のための栄養膜糖タンパク質（５ｔ４、ｔｐｂｇ）特異的キメラ抗原受容体 |
| US20170281683A1 (en) | 2014-09-26 | 2017-10-05 | Baylor College Of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| SG11201703309PA (en) | 2014-10-31 | 2017-05-30 | Baylor College Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| JP2018504894A (ja) | 2014-12-19 | 2018-02-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | キメラ抗原受容体およびその使用方法 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| BR112018067698A2 (pt) | 2016-02-25 | 2019-01-08 | Cell Medica Switzerland Ag | células modificadas para imunoterapia |
-
2017
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja active Active
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja active Active
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515646A5 (OSRAM) | ||
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2017536341A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| JP2018183173A5 (OSRAM) | ||
| JP2017522892A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| JP2019510733A5 (OSRAM) | ||
| JP2020525032A5 (OSRAM) | ||
| JP2019524693A5 (OSRAM) | ||
| JP2017526339A5 (OSRAM) | ||
| JP2019513009A5 (OSRAM) | ||
| JP2010500876A5 (OSRAM) | ||
| JP2018537421A5 (OSRAM) | ||
| JP2018537421A (ja) | Ｇｉｔｒアゴニスト | |
| JP2017529838A5 (OSRAM) | ||
| JP2017519501A5 (OSRAM) | ||
| JP2013527761A5 (OSRAM) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| JP2017518040A5 (OSRAM) | ||
| RU2021129189A (ru) | Антитела против фактора свертывания xi | |
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| JP2010509931A5 (OSRAM) | ||
| JPWO2020059847A5 (OSRAM) |